3.91
price down icon15.00%   -0.69
after-market アフターアワーズ: 4.00 0.09 +2.30%
loading
前日終値:
$4.60
開ける:
$4.58
24時間の取引高:
89,753
Relative Volume:
1.35
時価総額:
$101.53M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-23.03%
1か月 パフォーマンス:
-63.04%
6か月 パフォーマンス:
-65.40%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$3.90
$4.63
1週間の範囲:
Value
$3.90
$5.325
52週間の値動き範囲:
Value
$3.90
$17.31

Artiva Biotherapeutics Inc Stock (ARTV) Company Profile

Name
名前
Artiva Biotherapeutics Inc
Name
セクター
Healthcare (1183)
Name
電話
(858) 267-4467
Name
住所
5505 MOREHOUSE DRIVE, SAN DIEGO
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
ARTV's Discussions on Twitter

ARTV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARTV
Artiva Biotherapeutics Inc
3.91 101.53M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 122.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 78.30B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.73B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.47B 3.30B -501.07M 1.03B -2.1146

Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-30 開始されました H.C. Wainwright Buy
2024-08-13 開始されました Cantor Fitzgerald Overweight
2024-08-13 開始されました Jefferies Buy
2024-08-13 開始されました Needham Buy
2024-08-13 開始されました TD Cowen Buy
2024-08-13 開始されました Wedbush Outperform
すべてを表示

Artiva Biotherapeutics Inc (ARTV) 最新ニュース

pulisher
Feb 06, 2025

Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - In Vivo

Feb 06, 2025
pulisher
Feb 02, 2025

JPMorgan Chase & Co. Buys New Holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Feb 02, 2025
pulisher
Jan 31, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 31, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com South Africa

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics expands board with industry veteran By Investing.com - Investing.com South Africa

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics expands board with industry veteran - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members - Investing.com India

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan

Jan 29, 2025
pulisher
Jan 27, 2025

Natural killer cells, a rising alternative to CAR-T cell therapy - Yahoo Finance

Jan 27, 2025
pulisher
Jan 27, 2025

Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00 - Defense World

Jan 27, 2025
pulisher
Jan 24, 2025

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Predicts ARTV FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Weighs in on ARTV FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

Barclays PLC Buys Shares of 19,616 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Jan 21, 2025
pulisher
Jan 20, 2025

Artiva Biotherapeutics surges on trading debut - MSN

Jan 20, 2025
pulisher
Jan 14, 2025

Artiva Biotherapeutics announces pricing of upsized $167M IPO - MSN

Jan 14, 2025
pulisher
Jan 11, 2025

Aligos Therapeutics (NASDAQ:ALGS) & Artiva Biotherapeutics (NASDAQ:ARTV) Head to Head Contrast - Defense World

Jan 11, 2025
pulisher
Jan 08, 2025

Artiva Biotherapeutics, Inc.'s Lock-Up Period To End on January 15th (NASDAQ:ARTV) - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Artiva Biotherapeutics, Inc.’s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV) - Defense World

Jan 08, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Acquires Shares of 308,930 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Jan 06, 2025
pulisher
Jan 06, 2025

Barclays PLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

State Street Corp Invests $1.34 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

State Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Jan 03, 2025
pulisher
Jan 02, 2025

What is HC Wainwright’s Estimate for ARTV FY2024 Earnings? - Defense World

Jan 02, 2025
pulisher
Jan 02, 2025

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Average PT from Brokerages - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

Research Analysts Issue Forecasts for ARTV FY2024 Earnings - MarketBeat

Jan 01, 2025
pulisher
Dec 31, 2024

HC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy Recommendation - MSN

Dec 31, 2024
pulisher
Dec 31, 2024

Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for growth - Investing.com India

Dec 31, 2024
pulisher
Dec 30, 2024

Artiva Biotherapeutics’s SWOT analysis: NK cell therapy stock poised for growth - Investing.com Nigeria

Dec 30, 2024
pulisher
Dec 30, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC Wainwright - MarketBeat

Dec 30, 2024
pulisher
Dec 30, 2024

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Dec 30, 2024
pulisher
Dec 23, 2024

Franklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Dec 23, 2024
pulisher
Dec 20, 2024

Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart

Dec 20, 2024
pulisher
Dec 20, 2024

Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA - openPR

Dec 20, 2024
pulisher
Dec 20, 2024

BNP Paribas Financial Markets Invests $42,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Dec 20, 2024
pulisher
Dec 19, 2024

Charles Schwab Investment Management Inc. Invests $623,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World

Dec 19, 2024
pulisher
Dec 18, 2024

Wellington Management Group LLP Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Dec 18, 2024
pulisher
Dec 15, 2024

Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for autoimmune breakthrough - Investing.com India

Dec 15, 2024
pulisher
Dec 11, 2024

After Making the IPO Jump, Biotechs Landed On a Slippery Slope - BioSpace

Dec 11, 2024
pulisher
Dec 05, 2024

RA Capital Management L.P. Purchases Shares of 9,853,302 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

291,666 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by Samsara BioCapital LLC - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

RTW Investments LP Invests $2.30 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Dec 05, 2024
pulisher
Nov 28, 2024

Acuta Capital Partners LLC Purchases Shares of 44,000 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat

Nov 28, 2024

Artiva Biotherapeutics Inc (ARTV) 財務データ

Artiva Biotherapeutics Inc (ARTV) の財務データはありません。詳細については、他の銘柄を確認してください。

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Artiva Biotherapeutics Inc (ARTV) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
5AM Partners VI, LLC
10% Owner
Jul 22 '24
Buy
12.00
833,333
9,999,996
1,182,054
venBio Global Strategic Fund I
10% Owner
Jul 22 '24
Buy
12.00
416,666
4,999,992
1,936,637
GC Corp.
10% Owner
Jul 22 '24
Buy
12.00
1,666,666
19,999,992
3,306,900
GC Corp.
10% Owner
Jul 22 '24
Buy
12.00
416,666
4,999,992
1,260,512
Huh Yong-Jun
Director
Jul 22 '24
Buy
12.00
2,083,332
24,999,984
3,306,900
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
大文字化:     |  ボリューム (24 時間):